Steven Cohen's HAE Position Overview
Steven Cohen (via Point72 Asset Management, L.P.) currently holds 43.1K shares of Haemonetics Corporation (HAE) worth $2.1 M, representing 0.00% of the portfolio. First purchased in 2016-Q3, this long-term strategic position has been held for 37 quarters.
Based on 13F filings, Steven Cohen has maintained a strategic position in HAE, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2020, adding 849.7K shares. Largest reduction occurred in Q4 2020, reducing 1.4M shares.
Analysis based on 13F filings available since 2013 Q2
Steven Cohen's Haemonetics Corporation (HAE) Holding Value Over Time
Track share changes against reported price movement
Quarterly Haemonetics Corporation (HAE) Trades by Steven Cohen
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q3 2016 | +685,800 | New Buy | 685,800 | $36.21 |
| Q4 2016 | -603,742 | Reduce 88.03% | 82,058 | $40.20 |
| Q1 2017 | -82,058 | Sold Out | 82,058 | $0.00 |
| Q4 2017 | +477,200 | New Buy | 477,200 | $58.08 |
| Q1 2018 | -416,011 | Reduce 87.18% | 61,189 | $73.17 |
| Q2 2018 | -61,189 | Sold Out | 61,189 | $0.00 |
| Q3 2018 | +6,900 | New Buy | 6,900 | $114.64 |
| Q4 2018 | +796,862 | Add 11548.72% | 803,762 | $100.05 |
| Q1 2019 | +55,648 | Add 6.92% | 859,410 | $87.48 |
| Q2 2019 | -519,449 | Reduce 60.44% | 339,961 | $120.34 |
| Q3 2019 | -339,961 | Sold Out | 339,961 | $0.00 |
| Q1 2020 | +455,383 | New Buy | 455,383 | $99.66 |
| Q2 2020 | +361,442 | Add 79.37% | 816,825 | $89.56 |
| Q3 2020 | +849,744 | Add 104.03% | 1.67 M | $87.25 |
| Q4 2020 | -1.39 M | Reduce 83.17% | 280,432 | $118.75 |
| Q1 2021 | -90,732 | Reduce 32.35% | 189,700 | $111.01 |
| Q2 2021 | -99,100 | Reduce 52.24% | 90,600 | $66.64 |
| Q3 2021 | +175,500 | Add 193.71% | 266,100 | $70.59 |
| Q4 2021 | -266,100 | Sold Out | 266,100 | $0.00 |
| Q2 2022 | +408,897 | New Buy | 408,897 | $65.18 |
| Q3 2022 | +148,642 | Add 36.35% | 557,539 | $74.03 |
| Q4 2022 | -183,693 | Reduce 32.95% | 373,846 | $78.65 |
| Q1 2023 | -344,146 | Reduce 92.06% | 29,700 | $82.75 |
| Q2 2023 | -29,700 | Sold Out | 29,700 | $0.00 |
| Q4 2023 | +86,083 | New Buy | 86,083 | $85.51 |
| Q1 2024 | -7,383 | Reduce 8.58% | 78,700 | $85.35 |
| Q2 2024 | +140,324 | Add 178.30% | 219,024 | $82.73 |
| Q3 2024 | -219,024 | Sold Out | 219,024 | $0.00 |
| Q1 2025 | +420,930 | New Buy | 420,930 | $63.55 |
| Q2 2025 | +17,394 | Add 4.13% | 438,324 | $74.61 |
| Q3 2025 | -395,273 | Reduce 90.18% | 43,051 | $48.74 |
Steven Cohen's Haemonetics Corporation Investment FAQs
Steven Cohen first purchased Haemonetics Corporation (HAE) in Q3 2016, acquiring 685,800 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen has held Haemonetics Corporation (HAE) for 37 quarters since Q3 2016. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen's largest addition to Haemonetics Corporation (HAE) was in Q3 2020, adding 1,666,569 shares worth $145.41 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Steven Cohen's firm, Point72 Asset Management, L.P., owns 43,051 shares of Haemonetics Corporation (HAE), valued at approximately $2.1 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Haemonetics Corporation (HAE) represents approximately 0.00% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen's peak holding in Haemonetics Corporation (HAE) was 1,666,569 shares, as reported at the end of Q3 2020. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.